Trial Profile
Front-line Treatment of Ph Positive (Ph+)/Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) With Two Tyrosine Kinase Inhibitors (TKI) (Imatinib and Nilotinib). A Phase II Exploratory Multicentric Study in Elderly Patients and in Patients Unfit for Program of Intensive Therapy and Allogeneic Stem Cell Transplantation. GIMEMA Protocol LAL1408. EudraCT 2009-01327122
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary) ; Cytarabine; Dexamethasone; Methotrexate; Prednisone
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms GIMEMA LAL1408
- 10 Oct 2022 Status changed from active, no longer recruiting to completed.
- 12 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 03 Aug 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.